Keros jumps on plan to return $375M in excess capital

Keros Therapeutics (NASDAQ:KROS [https://seekingalpha.com/symbol/KROS]) has announced agreements to repurchase all shares of its common stock beneficially owned by each of ADAR1 Capital Management and Pontifax Venture Capital at a purchase price of $17.75 per share in cash.

The aggregate purchase price for the repurchase is around $181 million, which is expected to be funded from the company’s existing cash and cash equivalents. The transactions are expected to close on October 15, 2025, and are part of the company’s previously announced $375 million capital return program.

In connection with these transactions, Keros said it plans to distribute 25% of any net cash proceeds it receives on or before December 31, 2028, from its global license agreement with Takeda Pharmaceuticals U.S.A to stockholders.

Following the closing of the transactions with ADAR1 and Pontifax, Keros intends to commence a tender offer for up to $194 million in value of shares of the company’s common stock at a purchase price of $17.75 per share in cash. It presently plans to commence the tender offer by the end of October 2025.

KROS +7.4% premarket to $16.2

Source: Press Release [https://seekingalpha.com/pr/20266194-keros-therapeutics-announces-plan-for-return-of-375-million-in-excess-capital]

MORE ON KEROS THERAPEUTICS

* Keros Therapeutics: A Potential Dart Throw [https://seekingalpha.com/article/4825839-keros-therapeutics-a-potential-dart-throw]
* Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path [https://seekingalpha.com/article/4815817-keros-therapeutics-orphan-drug-win-for-dmd-candidate-a-small-step-on-right-path]
* Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset [https://seekingalpha.com/news/4487457-keros-gains-orphan-drug-designation-duchenne-muscular-dystrophy-asset]
* Seeking Alpha’s Quant Rating on Keros Therapeutics [https://seekingalpha.com/symbol/KROS/ratings/quant-ratings]
* Historical earnings data for Keros Therapeutics [https://seekingalpha.com/symbol/KROS/earnings]